<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00167544</url>
  </required_header>
  <id_info>
    <org_study_id>K23NS048152</org_study_id>
    <secondary_id>K23NS048152</secondary_id>
    <secondary_id>HSC-MS-05-0218</secondary_id>
    <nct_id>NCT00167544</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Hydrocortisone in Very Preterm High-Risk Infants</brief_title>
  <official_title>A Randomized Trial of Hydrocortisone in Very Preterm Infants at High Risk for Neurologic and Pulmonary Impairments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment of very preterm infants at
      high-risk for lung and brain injury with low dose hydrocortisone results in improved
      pulmonary and neurologic outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Among extremely low birth weight infants (ELBW; BW ≤ 1000 g) at high risk for
      bronchopulmonary dysplasia (BPD) and neurologic impairments, those infants randomized to
      seven days of hydrocortisone will demonstrate increased total cerebral tissue volumes as
      compared to infants randomized to placebo.

      Specific Aims: 1) To perform a pilot blinded randomized controlled trial of a 7-day regimen
      of low dose hydrocortisone in ELBW infants at high risk for BPD and neurosensory impairments
      and assess its effect on cerebral tissue volumes. 2) Evaluate and report 2 year
      neurodevelopmental outcomes.

      Background and Significance: Bronchopulmonary dysplasia is a disease of arrested lung
      development and lung inflammation. It is primarily seen in ELBW infants. Neurological delay,
      including cerebral palsy and mental retardation, affect up to 40%-50% of surviving ELBW
      infants. BPD is an important risk factor for such neurological delay. Postnatal
      administration of corticosteroids to ventilated preterm neonates results in a reduced risk of
      developing BPD. Postnatal corticosteroids however have shown harmful effects on the brain and
      can lead to increased rates of cerebral palsy and learning problems. This effect has
      primarily been seen with dexamethasone when high doses were given in the first week of life.
      Beyond the first week of life, there is insufficient information on the effects of steroids
      on the brain. Steroids other than dexamethasone, in much lower doses have been shown to
      improve short term lung function with minimal short-term side effects. A review study of all
      steroid trials for BPD shows that when given to a high risk group of infants (&gt; 50% risk of
      BPD) steroids protect the brain and reduce rates of cerebral palsy. The American and Canadian
      Pediatric societies and respected researchers have commented on the urgent need for more
      trials of other corticosteroids at lower doses started after the first week of life to
      evaluate their short and long-term pulmonary and neurological benefits and risks.

      Research Design and Methods:

        1. Inclusion &amp; Exclusion Criteria: See below.

        2. Procedures: Consented eligible patients will be randomly assigned to receive
           hydrocortisone in a tapering schedule over 7 days or placebo (comparison group). Study
           drug will be given every 12 hours IV with only study pharmacist aware of assignment. The
           patient's anatomic brain MRI (routinely done on all ELBW infants at 38 weeks
           post-menstrual age) will be further processed by the masked study investigators to
           derive total and regional brain volumes. Administration of indomethacin or dexamethasone
           to enrolled infants will be closely monitored and regulated throughout the trial period.
           Indomethacin use during study period is contraindicated. Dexamethasone (or other
           steroid) use will be restricted to ELBW infants on high ventilator settings (RIS &gt; 10)
           after 28 days of life. All other procedures will be per routine care. Blinded
           developmental follow-up at two years, already currently performed for all ELBW infants
           at MHCH, will be analyzed and reported for all study infants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Cerebral Volume as Measured by Volumetric Brain MRI</measure>
    <time_frame>38 weeks postmenstrual age (PMA)</time_frame>
    <description>Total cerebral volume included all brain gray matter and white matter, including cerebellum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regional Brain Volumes</measure>
    <time_frame>38-weeks postmenstrual age</time_frame>
    <description>Cerebral white matter volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Positive Pressure Support (Mechanical Ventilation or Continuous Positive Airway Pressure)</measure>
    <time_frame>Up to 36 weeks PMA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Oxygen Requirement</measure>
    <time_frame>Up to 36 weeks PMA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Without Severe Bronchopulmonary Dysplasia (BPD)</measure>
    <time_frame>36 weeks postmenstrual age</time_frame>
    <description>Using the NIH Consensus definition (Jobe A, 2001)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <condition>Encephalomalacia</condition>
  <condition>Premature Birth</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1. Tapering dose of hydrocortisone every 12 h over 7 day period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2. Identical-appearing saline placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Hydrocortisone 3 mg/kg/d divided q 12h IV/PO tapered over 7 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient in the Memorial Hermann Children's Hospital (MHCH) neonatal intensive care
             unit with a birth weight ≤ 1000 grams.

          -  Ventilator-dependent between 10 and 21 days of age.

          -  Respiratory index score (RIS: mean airway pressure x fraction of inspired oxygen) of ≥
             2.0 that is increasing or stable for the previous 24 hours or a RIS ≥ 3.0 if
             improvement noted in the past 24 hours.

        Exclusion Criteria:

          -  Prior postnatal steroid treatment.

          -  Evidence of sepsis or necrotizing enterocolitis.

          -  Known major congenital anomalies of the cardiopulmonary or central nervous system.

          -  Infants being treated with indomethacin or those likely to require treatment in the
             next 7 days as judged by the treating physician.

          -  Inability or unwillingness of parent or legal guardian/representative to give written
             informed consent.

          -  Gestational age &lt; 23 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nehal A. Parikh, D.O., M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Research Institute at Nationwide Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>432025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nhlbi.nih.gov/health/dci/Diseases/Bpd/Bpd_WhatIs.html</url>
    <description>Patient information page - Bronchopulmonary Dysplasia</description>
  </link>
  <reference>
    <citation>Parikh NA, Lasky RE, Kennedy KA, Moya FR, Hochhauser L, Romo S, Tyson JE. Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics. 2007 Feb;119(2):265-72.</citation>
    <PMID>17272615</PMID>
  </reference>
  <reference>
    <citation>Yu X, Zhang Y, Lasky RE, Datta S, Parikh NA, Narayana PA. Comprehensive brain MRI segmentation in high risk preterm newborns. PLoS One. 2010 Nov 8;5(11):e13874. doi: 10.1371/journal.pone.0013874.</citation>
    <PMID>21079730</PMID>
  </reference>
  <results_reference>
    <citation>Parikh NA, Kennedy KA, Lasky RE, McDavid GE, Tyson JE. Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional brain volumes. J Pediatr. 2013 Apr;162(4):685-690.e1. doi: 10.1016/j.jpeds.2012.09.054. Epub 2012 Nov 8.</citation>
    <PMID>23140612</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <results_first_submitted>March 25, 2013</results_first_submitted>
  <results_first_submitted_qc>July 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 30, 2013</results_first_posted>
  <last_update_submitted>July 29, 2013</last_update_submitted>
  <last_update_submitted_qc>July 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>Nehal Parikh</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Bronchopulmonary Dysplasia</keyword>
  <keyword>Encephalomalacia</keyword>
  <keyword>Brain injury</keyword>
  <keyword>Neurosensory impairment</keyword>
  <keyword>Corticosteroids</keyword>
  <keyword>Anti-Inflammatory Agents</keyword>
  <keyword>Extremely Low Birth Weight (ELBW) infants</keyword>
  <keyword>Premature Birth</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Encephalomalacia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All extremely low birth weight infants (ELBW; birth weight &lt;=1000g) that were mechanically ventilated between day of life 10 to 21 were screened for eligibility in the neonatal intensive care unit at Children's Memorial Hermann Hospital during the period of October 11, 2005 and September 8, 2008.</recruitment_details>
      <pre_assignment_details>Parent/guardian was approached if infant's respiratory index score (mean airway pressure x FiO2) was ≥ 2.0 and stable or increasing or if the respiratory index score was ≥ 3.0 when improvement was noted in the previous 24 hour period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Hydrocortisone Arm</title>
          <description>Subjects randomized by the investigational drug pharmacist to hydrocortisone arm received a 7 day course of intravenous (IV) hydrocortisone sodium succinate (Solu-Cortef) every 12 hours (3 mg/kg per day for first 4 days, 2 mg/kg per day for 2 days and 1 mg/kg per day for 1 day; total of 17 mg/kg over 7 days). The IV route was preferred.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Arm</title>
          <description>Subjects randomized by the investigational drug pharmacist to the placebo arm received an equivalent volume of identical appearing 0.9% sterile saline placebo. The IV route was preferred.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hydrocortisone Arm</title>
          <description>Subjects randomized by the investigational drug pharmacist to hydrocortisone arm received a 7 day course of intravenous (IV) hydrocortisone sodium succinate (Solu-Cortef) every 12 hours (3 mg/kg per day for first 4 days, 2 mg/kg per day for 2 days and 1 mg/kg per day for 1 day; total of 17 mg/kg over 7 days). The IV route was preferred.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Arm</title>
          <description>Subjects randomized by the investigational drug pharmacist to the placebo arm received an equivalent volume of identical appearing 0.9% sterile saline placebo. The IV route was preferred.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Gestational age</description>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="3" lower_limit="24" upper_limit="26"/>
                    <measurement group_id="B2" value="25" spread="3" lower_limit="24" upper_limit="27"/>
                    <measurement group_id="B3" value="25" spread="3" lower_limit="24" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Cerebral Volume as Measured by Volumetric Brain MRI</title>
        <description>Total cerebral volume included all brain gray matter and white matter, including cerebellum.</description>
        <time_frame>38 weeks postmenstrual age (PMA)</time_frame>
        <population>Eight infants died in each group prior to term MRI precluding a determination of brain volumes. Additionally, four infants had poor quality MRI scans that could not be analyzed for brain volumes.</population>
        <group_list>
          <group group_id="O1">
            <title>Hydrocortisone Arm</title>
            <description>Subjects randomized by the investigational drug pharmacist to hydrocortisone arm received a 7 day course of intravenous (IV) hydrocortisone sodium succinate (Solu-Cortef) every 12 hours (3 mg/kg per day for first 4 days, 2 mg/kg per day for 2 days and 1 mg/kg per day for 1 day; total of 17 mg/kg over 7 days). The IV route was preferred.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Subjects randomized by the investigational drug pharmacist to the placebo arm received an equivalent volume of identical appearing 0.9% sterile saline placebo. The IV route was preferred.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cerebral Volume as Measured by Volumetric Brain MRI</title>
          <description>Total cerebral volume included all brain gray matter and white matter, including cerebellum.</description>
          <population>Eight infants died in each group prior to term MRI precluding a determination of brain volumes. Additionally, four infants had poor quality MRI scans that could not be analyzed for brain volumes.</population>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272.01" spread="40.30"/>
                    <measurement group_id="O2" value="277.82" spread="59.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Regional Brain Volumes</title>
        <description>Cerebral white matter volume</description>
        <time_frame>38-weeks postmenstrual age</time_frame>
        <population>In addition to the reasons cited for the primary outcome, one infant in the hydrocortisone group and two in the placebo group had artifacts on brain MRI precluding cerebral white matter segmentation and volume determination.</population>
        <group_list>
          <group group_id="O1">
            <title>Hydrocortisone Arm</title>
            <description>Subjects randomized by the investigational drug pharmacist to hydrocortisone arm received a 7 day course of intravenous (IV) hydrocortisone sodium succinate (Solu-Cortef) every 12 hours (3 mg/kg per day for first 4 days, 2 mg/kg per day for 2 days and 1 mg/kg per day for 1 day; total of 17 mg/kg over 7 days). The IV route was preferred.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Subjects randomized by the investigational drug pharmacist to the placebo arm received an equivalent volume of identical appearing 0.9% sterile saline placebo. The IV route was preferred.</description>
          </group>
        </group_list>
        <measure>
          <title>Regional Brain Volumes</title>
          <description>Cerebral white matter volume</description>
          <population>In addition to the reasons cited for the primary outcome, one infant in the hydrocortisone group and two in the placebo group had artifacts on brain MRI precluding cerebral white matter segmentation and volume determination.</population>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.45" spread="18.73"/>
                    <measurement group_id="O2" value="118.62" spread="17.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis of total brain tissue volume was performed using multiple linear regression controlling for postmenstrual age at MRI scan to adjust for differences in timing at MRI. The distributions of potentially important confounding variables at baseline were compared in the two groups using parametric and non-parametric tests as appropriate. All analyses were performed using STATA 11.0. Please see PubMed: 23140612.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.49</ci_lower_limit>
            <ci_upper_limit>30.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Positive Pressure Support (Mechanical Ventilation or Continuous Positive Airway Pressure)</title>
        <time_frame>Up to 36 weeks PMA</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydrocortisone Arm</title>
            <description>Subjects randomized by the investigational drug pharmacist to hydrocortisone arm received a 7 day course of intravenous (IV) hydrocortisone sodium succinate (Solu-Cortef) every 12 hours (3 mg/kg per day for first 4 days, 2 mg/kg per day for 2 days and 1 mg/kg per day for 1 day; total of 17 mg/kg over 7 days). The IV route was preferred.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Subjects randomized by the investigational drug pharmacist to the placebo arm received an equivalent volume of identical appearing 0.9% sterile saline placebo. The IV route was preferred.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Positive Pressure Support (Mechanical Ventilation or Continuous Positive Airway Pressure)</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.7" lower_limit="63.4" upper_limit="74.0"/>
                    <measurement group_id="O2" value="65.9" lower_limit="59.7" upper_limit="72.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Oxygen Requirement</title>
        <time_frame>Up to 36 weeks PMA</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydrocortisone Arm</title>
            <description>Subjects randomized by the investigational drug pharmacist to hydrocortisone arm received a 7 day course of intravenous (IV) hydrocortisone sodium succinate (Solu-Cortef) every 12 hours (3 mg/kg per day for first 4 days, 2 mg/kg per day for 2 days and 1 mg/kg per day for 1 day; total of 17 mg/kg over 7 days). The IV route was preferred.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Subjects randomized by the investigational drug pharmacist to the placebo arm received an equivalent volume of identical appearing 0.9% sterile saline placebo. The IV route was preferred.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Oxygen Requirement</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" lower_limit="68.0" upper_limit="77.4"/>
                    <measurement group_id="O2" value="72.0" lower_limit="66.9" upper_limit="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival Without Severe Bronchopulmonary Dysplasia (BPD)</title>
        <description>Using the NIH Consensus definition (Jobe A, 2001)</description>
        <time_frame>36 weeks postmenstrual age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydrocortisone Arm</title>
            <description>Subjects randomized by the investigational drug pharmacist to hydrocortisone arm received a 7 day course of intravenous (IV) hydrocortisone sodium succinate (Solu-Cortef) every 12 hours (3 mg/kg per day for first 4 days, 2 mg/kg per day for 2 days and 1 mg/kg per day for 1 day; total of 17 mg/kg over 7 days). The IV route was preferred.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Subjects randomized by the investigational drug pharmacist to the placebo arm received an equivalent volume of identical appearing 0.9% sterile saline placebo. The IV route was preferred.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Without Severe Bronchopulmonary Dysplasia (BPD)</title>
          <description>Using the NIH Consensus definition (Jobe A, 2001)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hydrocortisone Arm</title>
          <description>Subjects randomized by the investigational drug pharmacist to hydrocortisone arm received a 7 day course of intravenous (IV) hydrocortisone sodium succinate (Solu-Cortef) every 12 hours (3 mg/kg per day for first 4 days, 2 mg/kg per day for 2 days and 1 mg/kg per day for 1 day; total of 17 mg/kg over 7 days). The IV route was preferred.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Arm</title>
          <description>Subjects randomized by the investigational drug pharmacist to the placebo arm received an equivalent volume of identical appearing 0.9% sterile saline placebo. The IV route was preferred.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death before NICU discharge</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Spontaneous intestinal perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nehal Parikh</name_or_title>
      <organization>Nationwide Children's Hospital Clinical Research Institute</organization>
      <phone>614-355-6657</phone>
      <email>nehal.parikh@nationwidechildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

